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 Parkinson’s disease (PD) is known to develop when there are decreased 
dopamine levels in the substantia nigra and development of alpha-synuclein neurons in 
the brain. However, recent studies have suggested that the gut-brain axis plays a large 
role in the development of PD. As a person ages, the cellular defense mechanisms in 
the gastrointestinal tract weakens, causing changes in the gut microbiota. This can 
eventually lead to changes such as dysbiosis, increased oxidative stress, and 
eventually alpha-synuclein neuron formation in the enteric nervous system in those who 
are susceptible to PD. The alpha-synuclein neurons spread to regions of the brain via 
the gut-brain axis. These changes along with other environmental factors can assist in 
the development of PD. Current L-DOPA treatment for PD are highly effective at 
minimizing symptoms, but can leave patients experiencing debilitating side effects 
during the “off” state when plasma L-DOPA levels are low. Researchers have been in 
search to improve treatment by exploring gastroretentive L-DOPA treatment and use of 
probiotics. Additionally, canines should be used as animal models for 
neurodegenerative disease research due to their various similarities to humans. 
Canines specifically are similar in their diets, digestive tract, aging process, and cerebral 
anatomy.  
Keywords: Parkinson’s disease, gut-brain axis, dopamine, alpha-synuclein neurons, 
oxidative stress, dysbiosis, gut microbiota, L-DOPA, probiotics, canine, animal models 
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Introduction 
 Parkinson’s Disease (PD) is the second most common neurodegenerative 
disease in the United States.1 It is estimated that by 2050, approximately 1.34 million 
people will be affected with PD in the United States.1 PD occurs when there is a 
decrease in active dopaminergic neurons in the substantia nigra, which leads to a 
decline in dopamine levels. Patients with PD also have been seen to possess misfolded 
alpha-synuclein neurons in the brain. This causes the impairment of controlled voluntary 
movement, 1,2,3 
 There are various symptoms that accompany PD. However, the main symptoms 
are split up into motor deficits and non-motor deficits. Motor deficits include muscle 
rigidity, resting tremor, and gait disturbances. Non-motor deficits tend to include 
decrease sense of smell, dementia, depression, and gastrointestinal (GI) disorders.4  
 There is currently no “cure” for PD. Current treatment options for PD are geared 
towards restoring dopaminergic transmission. This helps improve symptoms, but does 
not affect the neurodegenerative process.1 D2-like agonist can be used to increase 
dopaminergic signaling in the striatum. These have been seen to decrease motor 
deficits. There are also pharmaceutical treatments available that inhibit enzymes that 
catabolize dopamine, which can help increases availability of endogenous dopamine.1,5 
Currently, the most common treatment for PD is levodopa (L-DOPA), which is a 
precursor for dopamine. PD patients typically take L-DOPA orally several times per day 
and a peripheral decarboxylase inhibitor is most often used in combination. This allows 
the majority of treatment to reach the central nervous system (CNS) by inhibiting the 
conversion of L-DOPA to dopamine peripherally.6 L-DOPA is currently the most 
successful treatment for PD. However, many patients start to experience significant side 
effects with long-term use. These side effects include dyskinesia, hallucinations, 
increased cognitive impairment, depression, anxiety, and sleep disorders. 6 The “on-off” 
phenomenon refers to the pharmacokinetic effects of current L-DOPA treatment. 
Patients who take L-DOPA experience a rise and fall of plasma L-DOPA levels. When 
plasma L-DOPA levels are high, patients are seen to have fewer side effects. When 
plasma L-DOPA levels are lower, patient tend to experience dyskinesia, cognitive 
impairment, and other side effects. 7 This has been a large topic of discussion in PD 
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research. Researchers are interested in finding a noninvasive pharmaceutical treatment 
that can consistently keep plasma L-DOPA levels at a desired level.  
 The purpose of this literature review is to explore the connections between PD 
and the gut-brain axis. This review will also discuss alternative options to treatment, 
including gastroretentive L-DOPA treatment and probiotic use. Lastly, this review will 
discuss the use of canines as animal research models.  
 
Gut Microbiota and The Gut-Brain Axis 
 Gut microbiota refers to the various bacterial species that reside in the 
gastrointestinal tract.8 The bacterial community is diverse and each division has their 
own role. Bacteria in the gastrointestinal tract mainly consists of phyla Firmicutes and 
phyla Bacteriodietes.4,9,10,11 These species are referred to as beneficial flora and have 
many beneficial roles in regulating immunity and nutrition. Beneficial flora have the 
ability to ferment carbohydrates, produce short-chain fatty acids, metabolize various 
substances such as drugs, and protect the gastrointestinal tract from various 
pathogens.4 In contrast, opportunistic bacteria also reside in the gut and have the ability 
to cause infection.  Gastrointestinal disorders can begin to arise when dysbiosis occurs, 
which is characterized by an imbalance in beneficial flora and opportunistic bacteria.4 
 The gut-brain axis refers to the intimate relationship between the gastrointestinal 
tract and the brain. Recent studies have revealed an intricate bidirectional 
neuroendocrine system that allows both systems to communicate with each other. 8 The 
main contributors to the gut-brain axis involve the enteric nervous system (ENS), the 
central nervous system (CNS), and the gut microbiota. 8 These systems essentially 
come together to keep the gut and the mind healthy and at equilibrium. Disruption of 
this system have been suggested to cause various diseases, such as irritable bowel 
syndrome, anxiety, depression, dementia, and PD.12  
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Figure 1.  The gut-brain axis. This system is mainly composed of the central nervous 
system, enteric nervous system, and gut microbiota. Neuronal membrane formation can 
be influenced by dietary phospholipid precursors and cofactors, reducing inflammation. 
Probiotics, prebiotics, and synbiotics can also improve gut health by improving the 
composition of the gut microbiota.13  
 
Relationship of Parkinson’s Disease and the Gut-Brain Axis 
There are many factors that contribute to the relationship between PD and the 
gut-brain axis. PD has been linked environmental stressors, diet, and emotional stress. 
Environmental toxins, such as pesticides, can be found in the food humans consume 
and the environment we surround ourselves in.8,14 Age is a large factor in abnormal gut 
function. As we age, the cellular defense mechanisms in the gut weaken and damage is 
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more likely to be occur as the body is exposed to opportunistic bacteria and 
stressors.8,15 These various stressors can eventually cause disruption in the gut 
microbiota. Proportions of phyla Bacteriodetes and Firmicutes also fluctuate with age.8 
When dysbiosis occurs within the gut, the imbalance can result various gut dysfunction 
processes. This can lead to changes in the gut microbiota, oxidative stress and chronic 
low-grade inflammation. 8,16 Additionally, accumulation of alpha-synuclein neurons in the 
gastrointestinal tract has been discovered in patients with PD. 8  
Dysbiosis occurring within the gut can lead to many changes in the gut 
microbiota. With constant dysbiosis, these changes can become chronic and lead to 
long-term complications. A study including 72 patients diagnosed with PD and 72 
healthy control patients showed that there was a decreased amount of Prevotellaceace 
species in the feces of those who were diagnosed with PD compared to the healthy 
control patients. Prevotellaceace is a main producer of mucin, which is a protein that is 
highly glycosylated and provides protective barrier along the walls of the gut, preventing 
pathogens from entering.  Additionally, those who experienced postural instability and 
gait difficulty were seen to have more Enterobacteriacease in their feces. 
Enterobacteriacease has been seen in other feces of other neurodevelopment disorders 
as well, such as autism. It has been suggested that Enterobacteriacease is seen in 
more severe cases of PD and are questioning if it has an endotoxin-induce cascade.17  
In another study involving 38 patients affected by PD and 34 healthy controls, fecal 
samples and intestinal biopsies were taken from the sigmoid mucosa. Results showed a 
significant decrease in anti-inflammatory butyrate producing bacteria (genera Blautia, 
Coprococcus, and Roseburia) in patients with PD. Additionally, an increase in 
proinflammatory Proteobacteria of genus Ralstonia was seen in PD patients.18 It is 
shown that dysbiosis can lead to drastic changes in the gut microbiota that can 
contribute gastrointestinal issues and various symptoms that patients with PD may 
experience. In another study performed by Sampson et al. 2016, fecal microbiota from 
human patients diagnosed with PD was transferred to mice in order to identify if the gut 
microbiota would persist and affect disease outcomes. Germ free mice that were given 
human PD patient’s feces were referred to “humanized” mice. The control germ free 
mice were given feces from healthy patients. Results revealed that humanized mice 
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displayed significantly similar fecal microbiota to human patients with PD. The control 
group displayed larger differences in fecal microbiota than the healthy humans.19 This 
concluded that the differences in fecal microbiota remained persistent when transferred 
over to another organism.  
Oxidative stress has a large role in PD and can arise from various factors. 
Oxidative stress can occur when reactive oxidative species are overproduced. Reactive 
oxidative species (ROS) are produce in the mitochondria when electrons escape the 
electron transport chain. This mishap typically only occurs about 0.4-4% of time and a 
healthy host’s and antioxidant defense mechanisms typically take care of them without 
causing harm.8,20 However, with age related cellular degeneration and dysbiosis, this 
can cause various cellular and membrane damage that can eventually lead to cell 
death.8,15 Prolonged excessive ROS can lead to modifications in proteins, nucleic acids, 
and lipids. While many neurons in the brain typically can withhold oxidative stress fairly 
well, there are some regions that are more vulnerable than others. A study reviewed by 
Wilde et al. 1997, Vornov et al. 1998, Sarnowska, 2002, and Wang et al. 2005 looked 
into oxidative stress in the hippocampus. The hippocampus was chosen because of the 
density of neurons involved in this area of the brain. The hippocampus was split up into 
4 different regions, CA1 through CA4. Although regions CA1 and CA3 were composed 
in a similar structure containing pyramidal neurons, oxidative stress caused cell death to 
the pyramidal neurons of CA1. In contrast, most of the neurons in CA3 survived. This 
pattern of CA1 cell death to oxidative stress has specifically been seen in conditions, 
such as neurodegeneration and ischemia. 21 Oxidative stress can also change the 
metabolic and genomic expression of the microbiota population. These alterations can 
eventually cause physiological changes in the long run, changing how nutrients are 
metabolized and altering endocrine signaling.8,14  
	   	   Kimberly	  A.	  Dao	   7	  
 
Figure 2. The development of oxidative stress in PD. Release of reactive oxidative 
species is the leading cause of oxidative stress. However, this process can progress 
from various processes, such as neuroinflammation, mitochondrial dysfunction, 
impairment of dopamine release and storage, and impaired protein degradation.22 
 
Those affected with PD have been seen to experience chronic low-grade 
inflammation. When chronic inflammation is developed due to dysbiosis, it can lead to 
elevated cytokines and immune inflammatory cells that produce inflammatory 
mediators.8 Chronic inflammation can also cause an increase in vascular permeability 
leading to edema, increased concentration of blood in gastrointestinal tract, tissue 
ischemia, hypoxia, and stasis.23,24 Additionally, chronic inflammation can also lead to 
oxidative stress due to hypoxia. In order for the human body to adjust to this new 
environment, cell metabolism undergoes changes. These changes include delaying 
oxidative metabolism, conversion of xanthine dehydrogenase to oxidase, and depletion 
of adenosine triphosphate (ATP). Overall, these changes can also lead to reactive 
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oxygen intermediates (ROI) and this can either lead to oxygen reaching the cells but not 
being entirely reduced, or neutrophils reaching the inflamed portion and effecting the 
anaerobic glycolysis process, releasing ROI as a by-product. Changes in energy 
metabolism and disturbances in oxygen handling also occur when immune cells are 
activated. Oxidative phosphorylation is affected when macrophages fluctuate 
inflammatory activity.  Chronic inflammation causes these symptoms to constantly be 
activated, allowing the persistence of macrophages to effect anaerobic glycolysis, 
leading to oxidative stress. Overall, the body adapts with chronic shortages and 
redisposition of resources during chronic inflammation. There is a constant fluctuation 
between energy storage and energy consumption by organs, which leads to competition 
for nutrients.24  
 Accumulations of alpha-synuclein neurons have also been discovered in patients 
with PD and have been one of the largest topics of discussion. In a study performed by 
Shannon, Keshavarzian, Dodiya, Jakate, and Kordower, 2012, three old sigmoid 
mucosa biopsies were obtained from patients with known PD and analyzed for alpha-
synuclein by immunostaining. When compared to 23 healthy controls, it was found that 
all three samples from patients with known PD displayed alpha-synuclein pathology.25 It 
was also discussed that the samples were obtained 2-5 years prior to when patients 
initially showed motor deficits.25 This suggests that alpha-synuclein neurons form prior 
to development of neurological symptoms. The combination of low-grade inflammation 
and oxidative stress, alpha-synuclein develops in a similar pattern to prions.8 It is 
hypothesized that alpha-synuclein is developed in the gut over time due to 
enteroendocrine cells (EECs) taking up toxins from the basolateral surface. As more 
toxins are taken up over a long period of time, there is an abnormal accumulation of 
aggregated alpha-synuclein protein in the enteric nervous system, as seen in Figure 3 
.23,19 These alpha-synuclein proteins that develop in the gut are hypothesized to spread 
to the brain through the vagus nerve.19,26 Interestingly, it is seen that non-tremor 
dominant phenotype have been seen to have more severe alpha-synuclein pathology in 
the ENS. It has been suggested that this is linked to the higher amount of 
Enterobacteriacease.17 The accumulation of alpha-synuclein neurons has been one of 
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the main neurological hallmarks for PD. The presence of them in the gut emphasizes 
the connection between PD and the gut-brain axis.  
 
Figure 1. Enteroendocrine cells (EECs) are exposed to the lumen and in contact with 
various microbes, food, and toxins produced by gut microbes. The enteric nerve and 
glia is in contact with the basolateral surface of EECs. Aggregation of alpha-synucleins 
can occur depending on the toxins taken up by EEC. The aggregated proteins can 
migraine to enteric nerves, causing a pathogenic cascade. This can lead to abnormal 
accumulation of alpha-synuclein proteins in the gut.23 
 
 A study discussed by Sampson et al. 2016 was performed involving alpha-
synuclein overexpressing (ASO) mice. The experimental group of ASO mice was raised 
to have complex gut microbiota (SPF-ASO). The control groups were wild type ASO 
mice. There were four series of tests performed to assess motor function. The beam 
traversal and pole descent tests measured gross motor control. The nasal adhesive 
removal test measured fine motor control. Lastly, the hindlimb clasping reflex test 
assessed striatal dysfunction. Results showed that the SPF-ASO group took a longer 
time to complete the beam traversal and pole descent tests. Then nasal adhesive 
removal test was also took a significant amount longer in SPF-ASO mice. Lastly, the 
hindlimb clasping reflex test was impaired in SPF-ASO mice. To examine if gut 
microbiota contributed to these results, the researchers performed an additional study 
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that reestablished ASO mice (GF-ASO) and wild-type mice (GF-WT) in a germ-free 
environment. Both groups underwent the 4 series of motor tests and results showed a 
reduction in motor deficits in ASO mice. Additionally, researchers noticed that SPF-ASO 
mice experienced less fecal output than GF-ASO. The fecal output of SPF-ASO mice 
also contained less water than GF-ASO. Fecal output of GF-ASO was not changed 
compared to the GF-WT mice.19 This data indicates that gut microbiota has an effect on 
motor deficits and GI dysfunction. After performing immunofluorescence microscopy, 
Western blot, and dot blot analysis, the researchers reported a correlation between 
alpha-synuclein development in the CNS and gut microbiota. The GF-ASO mice 
displayed less alpha-synuclein development in the brain than the SPF-ASO mice.19  
  
L-DOPA on Gut 
 Dopamine is a known enteric neurotransmitter and is highly concentrated in the 
gastrointestinal tract. It has been seen that blocking dopamine receptors causes a 
decline in the gastroprotective qualities dopamine offers. Additionally, blocking alpha-2 
adrenoreceptors has also been seen to inhibit actions of dopamine and 
gastroprotection. There are many studies that have emphasized the connection 
between L-DOPA and the gastrointestinal tract. Some studies suggest that dopamine 
agonist have been discovered to prevent gastric injury induced by stress, ethanol, or 
medications.16 It has also been seen that dopamine agonist help prevent cysteamine-
induced duodenal ulcers.16,27 In contrast, dopamine antagonist increases cysteamine-
induced duodenal ulcers and has also been shown to enhance gastric lesions. 16 These 
effects indicate that endogenous dopamine might have an effect on gut health. A study 
was performed in 1996 investigating the effects of L-DOPA on gastric injury from 
ethanol.  L-DOPA was given intraperitoneally to female Sprague-Dawley rats who had 
known gastric injury from ethanol. It was shown that L-DOPA was able to prevent 
further macroscopic lesions from developing.  Additionally, the L-DOPA treatment was 
able to provide significant preservation of the gastric epithelium. 16  
 Another study performed in 2012 investigated the delivery methods of L-DOPA 
using 3 different extended release (ER) tablets in patients with idiopathic PD. They 
compared the conventional ER tablet taken 3 times daily, a L-DOPA/carbidopa 
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gastroretentive ER formulations taken 2 times daily, and an immediate release (IR) 
formulation with IR/ER and without ER. Results indicated that the gastroretentive option 
achieved a constant L-DOPA concentration in the plasma, which reduced side effects 
associated with the fluctuation of plasma L-DOPA concentrations.28 Using these results, 
researchers can consider developing gastroretentive L-DOPA treatment to avoid the 
“on-off” side effects caused by current L-DOPA treatment.  
 
Prevention of Gut Dysfunction Using Probiotics 
 Many PD patients have seen benefits from using probiotics to help improve their 
sensory responses and decrease gut inflammation, which overall improves motility.29 
Those who experience decline in nutrition may also benefit from prebiotic and probiotic 
therapy, since these are seen to help with absorption of nutrients.29  
 As stated before, age is an important factor in the progression of 
neurodegenerative diseases. Probiotics have been seen to help decrease some of the 
effects of aging that are known to assist in neurodegeneration, which include oxidative 
stress, cell apoptosis, and decrease neurotransmitters.8 Probiotics also help modulate 
neurological signaling in the gut, which overall improves inflammatory markers and 
reduces chronic inflammation.8 Some studies have also suggested that taking probiotics 
may help the integrity of the intestinal tract with the blood brain barrier.4 Additionally, 
some studies suggest that probiotics containing Lactobacilli and Bifidobacteria can 
actually reverse some side effects associated with PD. Probiotics that contain 
fermented milk contain Lactobacilli, which have been shown to decrease the amount of 
fecal Staphylococcus in patients with PD. The decrease in Staphylococcus has been 
seen to improve bowel movements. Bacterium Bacillus probiotics also have been 
suggested to convert L-tyrosine to L-DOPA. This is then converted to dopamine once 
DOPA decarboxylase is present.4 Overall, this suggest that the use of probiotics might 
be more beneficial than keeping the gut healthy, but also preventing the development of 
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Relevance of Canine Model for Research 
 Animal models are used in research to potentially help translate data to develop 
pharmaceuticals and treatments for humans. Rodents have traditionally been the animal 
models for various research studies, including neurodegenerative research. As more 
research is being performed over time, studies are revealing that there are multiple 
limitations to using rodents as animal models. A large limitation in neurodegenerative 
disease research is that there is a limited amount of animal species that mimic a similar 
gut-brain axis system as humans. However, as of recent there has been more research 
suggesting canines as an ideal animal model, especially for neurodegenerative and 
gastrointestinal research.30 This review will discuss the advantages of canines due to 
diet, digestive tract, aging process, and cerebral anatomy.  
 Humans and rodents have vastly different diets. Rodents typically consume a 
less complex diet than humans, which causes mice gut microbiota to be drastically 
different.30,31 Mice gut microbiota can produce enzymes that they do not typically 
consume, such as ascorbic acid.30,32  In contrast, humans consume a variety of different 
nutrients and do not synthesize the same enzymes as rodents do. Canines display a 
diet that is more closely related to humans and can adapt well to changes in diet.30 
Therefore, the gut microbiota in dogs may resemble humans more closely. Due to 
decades of domestication, canines also naturally live in an environment that most 
closely relates to a human’s environment. Canines deal with similar environmental 
factors to humans, in comparison to the mice.30,33 In addition, canines naturally have a 
diseased gastrointestinal tract when comparing to humans. This makes them good 
animal models for GI dysfunctions and neurodegenerative disorders. Therefore, canines 
are good disease models for diseases such as PD, Alzheimer’s disease (AD), and 
irritable bowel syndrome.30, 33, 34 
 Additionally, the aging process of rodents is not as parallel to humans as 
canines. Studies have shown that at age 5-9 years old, canines display similar cognitive 
aging process to middle aged humans between 40-60 years of age. Additionally, some 
species of canines experience canine multiple system degeneration (CMSD), which is 
an inheritable movement disorder. Dogs that have CMSD experience impaired voluntary 
movements due to degeneration to multiple brain regions, including the substantia 
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nigra, caudate nucleus, and cerebellum.30 Canines and humans also have similar brain 
structure and are described to have a gyrencephalic brain. In contrast, mice have a 
lissencephalic brain.30 These points emphasize the benefits of using canines for 
neurodegenerative movement disorders, such as PD.  
  
Conclusion 
 These findings help conclude that the cause of PD is multifactorial and cannot be 
pinpointed to one event. This review discusses how gut microbiota and the gut-brain 
axis influence the development of PD. The development of PD is suggested to stem 
from gut dysfunction years before symptoms develop. However, it is seen that the 
development of dysbiosis is caused by lifetime environmental factors.  
 Although L-DOPA is currently the main treatment for PD, researchers and 
pharmaceutical companies are continuously working to improve PD treatment. This 
review suggests that continuous plasma L-DOPA levels are important to limiting serious 
side effects. Gastroretentive L-DOPA treatments and probiotics have been suggested to 
help improve treatment and equilibrium of gut microbiota.  
  Lastly, this review discussed the benefits of using canines as animal models for 
research. Pertaining to neurodegenerative diseases and PD research, canines are 
suggested as the ideal animal model because of their gastrointestinal and cognitive 
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